Gomide Laura, Kummer Arthur, Cardoso Francisco, Teixeira Antonio Lucio
Movement Disorders Clinic, Service of Neurology, University Hospital, Federal University of Minas Gerais, Belo Horizonte, Brazil.
Arq Neuropsiquiatr. 2008 Sep;66(3B):611-4. doi: 10.1590/s0004-282x2008000500001.
Clozapine has been used as an attempt to manage levodopa complications in advanced Parkinson's disease (PD). To investigate the use of clozapine in this context in a Brazilian sample, a retrospective chart review was carried out at the Movement Disorders Clinic from the Federal University of Minas Gerais. This study enrolled 43 PD patients who used or were in use of clozapine. Patients had a mean age of 64 years and a mean UPDRS score of 55. Clozapine was indicated for dyskinesias in 17 patients, for psychosis in 15 and for both reasons in 11. The average maximum dose was 70 mg/day. Twenty six patients used it for a mean of 3.5 years. Twenty nine presented an improvement of their condition, 9 remained clinically stable. Twenty subjects interrupted the use of clozapine, being 9 due to adverse effects. Clozapine may play a role in the management of motor and psychiatric complications in PD, but it is associated with low tolerability.
氯氮平已被用于尝试处理晚期帕金森病（PD）的左旋多巴并发症。为了在巴西样本中研究氯氮平在此情况下的使用，米纳斯吉拉斯联邦大学运动障碍诊所进行了一项回顾性病历审查。本研究纳入了43名使用或正在使用氯氮平的PD患者。患者的平均年龄为64岁，平均统一帕金森病评定量表（UPDRS）评分为55分。氯氮平用于17例异动症患者、15例精神病患者以及11例因这两种原因使用的患者。平均最大剂量为70毫克/天。26名患者使用氯氮平的平均时间为3.5年。29名患者病情改善，9名患者临床保持稳定。20名受试者中断使用氯氮平，其中9名是由于不良反应。氯氮平可能在PD的运动和精神并发症管理中发挥作用，但它与耐受性低有关。
